CP101
FIN-CDI-301
Phase 3 mab terminated
Quick answer
CP101 for Recurrent C. Difficile Infection is a Phase 3 program (mab) at Finch Therapeutics Group with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Finch Therapeutics Group
- Indication
- Recurrent C. Difficile Infection
- Phase
- Phase 3
- Modality
- mab
- Status
- terminated